BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25088578)

  • 1. Circulating TGF-β1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores.
    Dituri F; Serio G; Filannino D; Mascolo A; Sacco R; Villa E; Giannelli G
    Cancer Lett; 2014 Oct; 353(2):264-71. PubMed ID: 25088578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
    Giannelli G; Santoro A; Kelley RK; Gane E; Paradis V; Cleverly A; Smith C; Estrem ST; Man M; Wang S; Lahn MM; Raymond E; Benhadji KA; Faivre S
    PLoS One; 2020; 15(3):e0222259. PubMed ID: 32210440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging.
    Yegin EG; Siykhymbayev A; Eren F; Bekiroglu N; Ozdogan OC
    Ann Hepatol; 2013; 12(6):915-25. PubMed ID: 24114822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
    Dong ZZ; Yao DF; Yao M; Qiu LW; Zong L; Wu W; Wu XH; Yao DB; Meng XY
    Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):288-95. PubMed ID: 18522884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma.
    Ji F; Fu SJ; Shen SL; Zhang LJ; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
    BMC Cancer; 2015 Mar; 15():116. PubMed ID: 25880619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
    Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
    Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
    Lin TH; Shao YY; Chan SY; Huang CY; Hsu CH; Cheng AL
    Clin Cancer Res; 2015 Aug; 21(16):3678-84. PubMed ID: 25977342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming Growth Factor-β1 as a Predictor for the Development of Hepatocellular Carcinoma: A Nested Case-Controlled Study.
    Watanabe Y; Iwamura A; Shimada YJ; Wakai K; Tamakoshi A; Iso H;
    EBioMedicine; 2016 Oct; 12():68-71. PubMed ID: 27614396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer.
    Lacin S; Yalcin S
    Technol Cancer Res Treat; 2020; 19():1533033820971677. PubMed ID: 33234055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma.
    Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
    Br J Cancer; 1997; 76(2):244-50. PubMed ID: 9231926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.
    Kaseb AO; Morris JS; Hassan MM; Siddiqui AM; Lin E; Xiao L; Abdalla EK; Vauthey JN; Aloia TA; Krishnan S; Abbruzzese JL
    J Clin Oncol; 2011 Oct; 29(29):3892-9. PubMed ID: 21911725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.
    Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
    Br J Cancer; 1997; 75(10):1460-6. PubMed ID: 9166938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.
    Fan QM; Jing YY; Yu GF; Kou XR; Ye F; Gao L; Li R; Zhao QD; Yang Y; Lu ZH; Wei LX
    Cancer Lett; 2014 Oct; 352(2):160-8. PubMed ID: 24892648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
    Fransvea E; Angelotti U; Antonaci S; Giannelli G
    Hepatology; 2008 May; 47(5):1557-66. PubMed ID: 18318443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium.
    Benetti A; Berenzi A; Gambarotti M; Garrafa E; Gelati M; Dessy E; Portolani N; Piardi T; Giulini SM; Caruso A; Invernici G; Parati EA; Nicosia R; Alessandri G
    Cancer Res; 2008 Oct; 68(20):8626-34. PubMed ID: 18922939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection.
    Ji F; Zhang ZH; Zhang Y; Shen SL; Cao QH; Zhang LJ; Li SQ; Peng BG; Liang LJ; Hua YP
    BMC Cancer; 2018 Apr; 18(1):460. PubMed ID: 29690860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
    Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
    Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation.
    Zhang W; Kim R; Quintini C; Hashimoto K; Fujiki M; Diago T; Eghtesad B; Miller C; Fung J; Tan A; Menon KV; Aucejo F
    Liver Transpl; 2015 Jan; 21(1):101-11. PubMed ID: 25283528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-beta1 and C-erb-B2 neu oncoprotein in Egyptian HCV related chronic liver disease and hepatocellular carcinoma patients.
    El Bassuoni MA; Talaat RM; Ibrahim AA; Shaker OT
    Egypt J Immunol; 2008; 15(1):39-50. PubMed ID: 20306668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.